MWMary Wangen

Mary Wangen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary Wangen has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding access to colorectal cancer screening through community pharmacies: study protocol for the PharmFIT™ randomized controlled trial

    by Morgan Glascock, Mary Wangen, Renee M. Ferrari, Meghan C. O&Apos;Leary, Jessie Schwartz, Michelle Ndugulile, Joseph M. Unger, Catherine Fedorenko, Li Li, Macary Weck Marcinkiak, et al.

    Background. Colorectal cancer (CRC) is a leading cause of cancer death. Fecal immunochemical test (FIT) screening remains underused, particularly in underserved communities. Community pharmacies are highly accessible and increasingly deliver preventive care, yet pharmacy-based CRC screening has not been tested in a large pragmatic randomized trial with concurrent implementation and economic evaluation. This protocol describes a pragmatic trial testing a pharmacy-based CRC screening intervention using FIT, called PharmFIT™, which integrates community pharmacies into CRC screening pathways for primary care patients due for screening.Methods. PharmFIT™ is a two-arm, pragmatic, hybrid type 1 effectiveness–implementation trial in two geographically disparate states (Washington and North Carolina). Adults aged 45–75 years, due for CRC screening, are randomized (n=1,200) to PharmFIT™ or usual care. In the intervention arm, clinics recommend CRC screening and refer patients to partner pharmacies, and pharmacists counsel patients, dispense FIT kits, and support kit return and follow-up. The primary outcome is completion of any United States Preventive Services Task Force–recommended CRC screening test within 6 months. Secondary outcomes include reach, timeliness of FIT completion and follow-up colonoscopy, and screening differences across patient subgroups. Implementation outcomes (acceptability, appropriateness, feasibility, fidelity, cost) are assessed using mixed methods, and economic analyses estimate intervention implementation costs, incremental cost per additional patient screened, and budget impact conducted from pharmacy and societal perspectives.Conclusions. PharmFIT™ will provide effectiveness, implementation, and cost evidence for pharmacy-based CRC screening, informing the scalability of pharmacist-led cancer prevention within primary care.

  • Open Access

    Scaling what works: a collaborative capacity-building program tailored to optimize resources and scale evidence-based interventions for cancer prevention and control

    by Mary Wangen, Jingle Xu, Amy Tran, Elizabeth A. Rohan, Prajakta Adsul, Cam Escoffery, Renée M. Ferrari, Nikki Hayes, Cari Herington, Katie Jones, et al.

    This study aimed to evaluate the Scaling What Works (SWW) program, which was developed to support the scale-up of projects that implement evidence-based cancer prevention and control interventions (CPC EBIs) across award recipients (hereafter, "awardees") of the National Comprehensive Cancer Control Program (NCCCP). SWW projects included (1) Project ECHO and patient navigation, (2) Addressing risk factors for adult cancers during childhood, and (3) Increasing receipt of ovarian cancer care from gynecologic oncologists. In this evaluation, we sought to understand how tailored training and technical assistance (TA) can facilitate the implementation of CPC EBIs in NCCCP settings. We used a mixed-methods approach, comprising a needs assessment with focus groups and information sessions. Subsequent training and TA included a symposium and four virtual learning collaborative sessions. The evaluation included pre- and post-surveys to assess changes in participants' confidence and satisfaction alongside qualitative feedback to refine the program. The SWW program reached 89 individuals across 40 NCCCP awardees. Participants reported significant improvements in their confidence to implement, adapt, and sustain EBIs, with increases observed in all domains assessed. Feedback from the symposium and learning collaborative sessions indicated high satisfaction and notable progress in addressing barriers related to EBI implementation. The SWW program effectively addressed key challenges in scaling CPC interventions by providing tailored, interactive training and TA. Further engagement and continued capacity-building support are recommended to enhance the long-term impact of SWW across the NCCCP. The findings underscore the importance of investing in tailored, large-scale capacity-building to support the scale-up of evidence-based CPC approaches.

  • Open Access

    Designing a colorectal cancer screening program for community pharmacies: Findings from a national survey of pharmacists

    by Parth D. Shah, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Renée Ferrari, Macary W. Marciniak, Stephanie B. Wheeler, Alison T. Brenner

  • Open Access

    Data from It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Background:Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT.Methods:From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based colorectal cancer screening program (PharmFIT). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT.Results:Most pharmacists (80%) were willing to implement PharmFIT. The most common reasons for unwillingness were that results needed to be reported to the patients’ primary care providers (52%), that appropriate training in delivering colorectal cancer screening be provided (48%), and that care coordination with primary care providers be clear (46%). Perceived complexity of the intervention decreased as years in practice increased [β = 0.013; 95% confidence interval (CI), 0.01–0.02] and as the level of knowledge about colorectal cancer screening increased (β = 0.085; 95% CI, 0.01–0.16). Respondents’ willingness to implement PharmFIT increased as perceived complexity decreased (OR = 5.68; 95% CI, 3.96–8.15).Conclusions:Most community pharmacists in the United States would be willing to integrate PharmFIT into their current workflows. Training in how to deliver fecal immunochemical testing and preparation for the coordination of test results and follow-up care should be completed prior to implementing PharmFIT.Impact:Community pharmacies are a viable venue for delivering colorectal cancer screening.

  • Open Access

    Supplementary Figure 1 from It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Supplementary Figure 1. A flow diagram depicting the composition of the analytic samples for the outcomes of “Willingness to provide PharmFIT” and “Complexity of PharmFIT”.

  • It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening

    by Alison T. Brenner, Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Parth D. Shah

    Background: Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT. Methods: From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based colorectal cancer screening program (PharmFIT). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT. Results: Most pharmacists (80%) were willing to implement PharmFIT. The most common reasons for unwillingness were that results needed to be reported to the patients’ primary care providers (52%), that appropriate training in delivering colorectal cancer screening be provided (48%), and that care coordination with primary care providers be clear (46%). Perceived complexity of the intervention decreased as years in practice increased [β = 0.013; 95% confidence interval (CI), 0.01–0.02] and as the level of knowledge about colorectal cancer screening increased (β = 0.085; 95% CI, 0.01–0.16). Respondents’ willingness to implement PharmFIT increased as perceived complexity decreased (OR = 5.68; 95% CI, 3.96–8.15). Conclusions: Most community pharmacists in the United States would be willing to integrate PharmFIT into their current workflows. Training in how to deliver fecal immunochemical testing and preparation for the coordination of test results and follow-up care should be completed prior to implementing PharmFIT. Impact: Community pharmacies are a viable venue for delivering colorectal cancer screening.


  • Synergies, partnership outcomes, and lessons learned: a qualitative evaluation of cancer center–coalition engagement

    by Aubrey Villalobos, Paula Darby Lipman, Jennifer Beebe-Dimmer, Evelinn A Borrayo, Katherine J Briant, Amanda Bruegl, Craig Dee, Sarah Chavez, Bettina Drake, Selisha Snowy Johnson, et al.

    Background: Nine National Cancer Institute–Designated Cancer Centers received supplemental funding to expand community outreach and engagement activities through a partnership with Centers for Disease Control and Prevention–funded comprehensive cancer control coalitions. This article reports on an evaluation of these awards focused on organizational relationships and partnership outcomes. Methods: The National Cancer Institute, community outreach and engagement, and coalition representatives co-designed the evaluation, which involved document review and 18 semistructured interviews with 16 community outreach and engagement and 19 coalition representatives. Artificial intelligence–generated interview transcripts were dual-coded in NVivo, version 20/R1, software. Results: The funding generated a diverse collection of projects and partnerships. Community outreach and engagement–coalition synergies and lessons learned were evident in the following domains: infrastructure; community and partner engagement; data monitoring; and intervention implementation, evaluation, and dissemination. Outcomes of this funding initiative were evident in the following domains: strengthened partnerships, expanded knowledge, improved health or health-care programs and policies, and thriving communities. Conclusions: Fostering community outreach and engagement–coalition partnerships created opportunities to use synergies and build capacity for engagement across multiple domains, contributing to enhanced trust and implementation of interventions across the cancer continuum. The findings provide examples and lessons on which cancer centers and coalitions can capitalize. Successful collaborative relationships were based on identifying shared goals and complementary expertise and roles, sharing financial and other resources, and a commitment to authentic and open dialogue. Although modest and short term, supplemental funding can strengthen organizational relationships and promote effective collaboration on community-facing activities; it can also lead to improved research engagement and translation of evidence to practice.

  • Open Access

    Findings From a National Survey of Older US Adults on Patient Willingness to Use Telehealth Services: Cross-Sectional Survey

    by Olufeyisayo O Odebunmi, Tamera D Hughes, Austin R Waters, Benjamin Y Urick, Caroline Herron, Mary Wangen, Catherine Rohweder, Renée M Ferrari, Macary W Marciniak, Stephanie B Wheeler, et al.

    Background: Telehealth (telemedicine and telepharmacy) services increase access to patient services and ensure continuity of care. However, few studies have assessed factors that influence patients’ willingness to use telehealth services, and we sought to investigate this. Objective: This study aims to examine respondents’ (aged between 45 and 75 years) willingness to use telehealth services (telepharmacy and telemedicine) and the correlates of the willingness to use telehealth services. Methods: We administered a cross-sectional national survey of 1045 noninstitutionalized US adults aged between 45 and 75 years in March and April 2021. Multiple logistic regression analyses were used to identify demographic and health service use correlates of self-reported willingness to use telehealth services. Results: Overall willingness to use telemedicine was high (674/1045, 64.5%). Adults aged 55 years and older were less willing to use telemedicine (aged between 55 and 64 years: odds ratio [OR] 0.61, 95% CI 0.42-0.86; aged 65 years or older: OR 0.33, 95% CI 0.22-0.49) than those younger than 55 years. Those with a regular provider (OR 1.01, 95% CI 1-1.02) and long travel times (OR 1.75, 95% CI 1.03-2.98) were more willing to use telemedicine compared to those without a regular provider and had shorter travel times, respectively. Willingness to use telemedicine services increased from 64.5% (674/1045) to 83% (867/1045) if the service was low-cost or insurance-covered, was with their existing health care provider, or was easy-to-use. Overall willingness to use telepharmacy was 76.7% (801/1045). Adults aged older than 55 years were less willing to use telepharmacy (aged between 55 and 64 years: OR 0.57, 95% CI 0.38-0.86; aged 65 years or older: OR 0.24, 95% CI 0.15-0.37) than those younger than 55 years. Those who rated pharmacy service quality higher were more willing to use telepharmacy (OR 1.06, 95% CI 1.03-1.09) than those who did not. Conclusions: Respondents were generally willing to use telehealth (telemedicine and telepharmacy) services, but the likelihood of their being willing to use telehealth decreased as they were older. For those initially unwilling (aged 55 years or older) to use telemedicine services, inexpensive or insurance-covered services were acceptable.


  • Open Access

    How pharmacists would design and implement a community pharmacy-based colorectal cancer screening program

    by Austin R. Waters, Katherine Meehan, Dana L. Atkins, Annika H. Ittes, Renée M. Ferrari, Catherine L. Rohweder, Mary Wangen, Rachel M. Ceballos, Rachel B. Issaka, Daniel S. Reuland, et al.

    Distributing CRC screening through pharmacies, a highly accessible health service, may create opportunities for more equitable access to CRC screening. However, providing CRC screening in a new context introduces a substantial implementation challenge. We conducted 23 semi-structured interviews with community pharmacists practicing in Washington state and North Carolina about distributing fecal immunochemical tests (FIT) to patients in the pharmacy. The Consolidated Framework for Implementation Research (CFIR) was used to guide analysis. Pharmacists believed that delivering FITs was highly compatible with their environment, workflow, and scope of practice. While knowledge about FIT eligibility criteria varied, pharmacists felt comfortable screening patients. They identified standardized eligibility criteria, patient-facing educational materials, and continuing education as essential design features. Pharmacists proposed adapting existing pharmacy electronic health record systems for patient reminders/prompts to facilitate FIT completion. While pharmacists felt confident that they could discuss test results with patients, they also expressed a need for stronger communication and care coordination with primary care providers. When designing a pharmacy-based CRC screening program, pharmacists desired programmatic procedures to fit their current knowledge and context. Findings indicate that if proper attention is given to multi-level factors, FIT delivery can be extended to pharmacies.


  • Open Access

    Supplemental Figure S1 from Patient Willingness to Use a Pharmacy-Based Colorectal Cancer Screening Service: A National Survey of U.S. Adults

    by Parth D. Shah, Mary Wangen, Catherine L. Rohweder, Austin R. Waters, Olufeyisayo O. Odebunmi, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Alison T. Brenner

    Measurement model for Diffusion of Innovation latent variables relative advantage, compatibility, and complexity.